367 related articles for article (PubMed ID: 21042281)
21. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
[TBL] [Abstract][Full Text] [Related]
22. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6- and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis.
Khan KN; Masuzaki H; Fujishita A; Kitajima M; Hiraki K; Sekine I; Matsuyama T; Ishimaru T
Hum Reprod; 2005 Oct; 20(10):2715-23. PubMed ID: 16006475
[TBL] [Abstract][Full Text] [Related]
25. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).
Mustjoki S; Borze I; Lasho TL; Alitalo R; Pardanani A; Knuutila S; Juvonen E
Leuk Res; 2009 Jan; 33(1):54-9. PubMed ID: 18760472
[TBL] [Abstract][Full Text] [Related]
26. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor.
Matsuda-Hashii Y; Takai K; Ohta H; Fujisaki H; Tokimasa S; Osugi Y; Ozono K; Matsumoto K; Nakamura T; Hara J
Exp Hematol; 2004 Oct; 32(10):955-61. PubMed ID: 15504551
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
[TBL] [Abstract][Full Text] [Related]
29. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
[TBL] [Abstract][Full Text] [Related]
30. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
31. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
33. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.
da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF
Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287
[TBL] [Abstract][Full Text] [Related]
34. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
35. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
36. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
37. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
38. A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.
Casolari DA; Nguyen T; Butcher CM; Iarossi DG; Hahn CN; Bray SC; Neufing P; Parker WT; Feng J; Maung KZY; Wee A; Vidovic L; Kok CH; Bardy PG; Branford S; Lewis ID; Lane SW; Scott HS; Ross DM; D'Andrea RJ
Sci Rep; 2017 May; 7(1):2467. PubMed ID: 28550306
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
